# Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008)

> **NCT02070757** · PHASE3 · COMPLETED · sponsor: **Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 726 (actual)

## Conditions studied

- Healthcare-Associated Pneumonia
- Ventilator-Associated Pneumonia
- Lung Diseases

## Interventions

- **DRUG:** Ceftolozane/tazobactam
- **DRUG:** Meropenem

## Key facts

- **NCT ID:** NCT02070757
- **Lead sponsor:** Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09-02
- **Primary completion:** 2018-05-15
- **Final completion:** 2018-06-06
- **Target enrollment:** 726 (ACTUAL)
- **Last updated:** 2020-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02070757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02070757, "Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02070757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*